Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

News

Year

Clene rockets on positive data for CNM-Au8 in ALS

July 15, 2022

True test for Clene’s ALS survival comes next

July 14, 2022

Tech Nation Radio Podcast: Episode 22-28 The Science: Feelings before Knowledge

July 8, 2022

A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs

July 8, 2022

CNM-Au8 Extends Survival, RESCUE-ALS Study Suggests

June 9, 2022

BioWorld Insider Podcast: New Therapies Vie to Change Fatal Course of Amyotrophic Lateral Sclerosis

June 3, 2022

Finding Genius Podcast: Restoring And Protecting Neurological Function Using Revolutionary Treatments

June 2, 2022

VIDEO: Survival improved among ALS patients treated with nanocrystal gold

April 13, 2022

Nanocrystalline Gold Treatment Slows Clinical Decline in Amyotrophic Lateral Sclerosis

April 8, 2022

Nanoparticle Shows Promise for ALS

April 7, 2022

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Next page
Last page

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved